(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 December 2011 (01.12.2011)

PCT

(10) International Publication Number
WO 2011/150284 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 37/00* (2006.01)
A61P 31/00 (2006.01)

(21) International Application Number:
PCT/US2011/038247

(22) International Filing Date:
26 May 2011 (26.05.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

2010202125	26 May 2010 (26.05.2010)	AU
12/789,365	27 May 2010 (27.05.2010)	US
12/842,944	23 July 2010 (23.07.2010)	US

(71) Applicants *(for all designated States except US)*: **BAXTER INTERNATIONAL INC.** [US/US]; One Baxter Parkway, Deerfield, IL 60015 (US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thurgauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **TESCHNER, Wolfgang** [DE/AT]; Gestettengasse 19/14, A-1030 Vienna (AT). **SCHWARZ, Hans-Peter** [AT/AT]; Weimarer Strasse 76, A-1180 Vienna (AT). **MADLENER, Ruth** [AT/AT]; Grobe Pfarrgasse 6/9, A-1020 Vienna (AT). **SVATOS, Sonja** [AT/AT]; Kapellengasse 42, A-2413 Berg (AT). **PLJEVLJAKOVIC, Azra** [AT/AT]; Ottakringerstrasse 94/22, A-1170 Vienna (AT). **WEBER, Alfred** [AT/AT]; Skraupstrasse 24/42/8, A-1210 Vienna (AT).

(74) Agent: **PARENT, Annette, S.**; MORGAN, LEWIS & BOCKIUS LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: REMOVAL OF SERINE PROTEASES BY TREATMENT WITH FINELY DIVIDED SILICON DIOXIDE




FIG. 3

(57) Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

WO 2011/150284 A2

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*